# US 11,077,093 B2 · Combination drug

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,077,093 B2
- Document ID: US11077093B2
- Status: Granted
- Kind: B2
- Application number: 15/543,033
- Filed: 2016-01-15
- Published: 2018-01-04
- Granted: 2021-08-03
- Earliest claimed: 2015-01-16
- Assignees: Chugai Seiyaku Kabushiki Kaisha
- Applicants: Chugai Seiyaku Kabushiki Kaisha
- Inventors: Hiroshi Sakamoto; Toshiyuki Tsukaguchi
- Web page: https://patentgrep.com/patent/US11077093B2

## CPC

- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5355: Non-condensed oxazines and containing further heterocyclic rings
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a drug that is for treating or preventing cancer, that is effective in the treatment of cancer, and that comprises a combination of an ALK inhibitor and a VEGF inhibitor. The present invention also relates to a method for treating or preventing cancer and a method for inhibiting tumor growth.

## Claims

### Claim 1

A method of enhancing a therapeutic effect of an ALK inhibitor on a cancer, the method comprising: administering, in combination, an effective amount of the ALK inhibitor and an effective amount of a VEGF inhibitor to a subject in need thereof, wherein the ALK inhibitor is alectinib or a salt thereof and the VEGF inhibitor is bevacizumab and wherein said administering the effective amount of the VEGF inhibitor enhances a therapeutic effect of the ALK inhibitor on the cancer in the subject, wherein the cancer comprises a tumor that has an ALK fusion gene, the alectinib or the salt thereof is administered at a dose of 20 mg, 40 mg, 60 mg, 80 mg, 120 mg, 160 mg, 220 mg, 240 mg, 300 mg, 460 mg, 600 mg, 760 mg or 900 mg calculated as a free form twice a day and the bevacizumab is administered at 5 mg/kg, 7.5 mg/kg, 10 mg/kg or 15 mg/kg, wherein the ALK fusion gene is a fusion gene of ALK gene and EML4-gene and wherein the cancer is selected from the group consisting of non-Hodgkin's lymphoma, neuroblastoma, renal cancer, and lung cancer.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the VEGF inhibitor is administered simultaneously with the ALK inhibitor.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the VEGF inhibitor is administered prior to or after the administration of the ALK inhibitor.

### Claim 4 (depends on 1)

The method of claim 1, which is a method of treating the cancer.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cancer is lung cancer.

### Claim 6 (depends on 4)

The method of claim 4, wherein the cancer is lung cancer.